| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Heron Therapeutics, Inc.$0.41
-0.01 (-2.01%)
C 58Pipeline Score Undervalued Biotech · Commercial
Market Cap
162.55 M
EPS
-0.18
P/E Ratio
-
Value Trade
4.94 M
SEC Financials
Q1 2026Dilution Risk
Revenue
34.71 M
R&D Expenses
2.38 M
Operating CF
-1.54 M
Total Assets
246.22 M
Total Liabilities
237.08 M
Equity
9.14 M
D/E Ratio
12,345
-7.66 %
Week
-17.42 %
1 Month
-28.43 %
3 Month
-16.62 %
6 Month
-94 %
5 Year
-99.85 %
All Time
Cash Data
Cash Position
44.80 M
Monthly Burn
513.00 K
Runway
85.5 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
2.71 M
52 Week Range
0.74 - 2.30
% held by Insiders
7.53 %
% held by Institutions
76.53 %
Enterprise Value
260.45 M
Total Shares
188.54 M
Short %
29.71 %
Float Shares
136.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Heron Therapeutics, Inc.
432Total events
5Upcoming
162Tier-1 (high impact)
2011 – 2032Coverage
Upcoming catalysts 5
2027
T1FDA Approval
FDA approval of proposed Prefilled Syringe market presentation anticipated in mid-to-late 2027
2027
T2Timing Guidance
ZYNRELEF Prefilled Syringe program stability commenced; approval anticipated in 2027
Q1 2027
T3Manufacturing Milestone
Registration batches for ZYNRELEF prefilled syringe placed on stability; 12-month stability data expected Q1 2027
Event history 427
Q3 2026
▲Timing GuidancePresentation
Planned sales force expansion for Acute Care franchise on track for Q3 2026
Jun 2, 2026
▼IP Litigation RulingCINVANTIApprovedIP / Competition
U.S. District Court holds CINVANTI patents invalid
chemotherapy-induced nausea and vomitingsource ↗
Apr 28, 2026
▲IP Litigation RulingCINVANTIApprovedIP / Competition
Settlement reached with Baxter Healthcare Corporation in CINVANTI patent litigation; case dismissed
chemotherapy-induced nausea and vomitingsource ↗
Apr 1, 2026
▲Timing GuidanceAPONVIEApprovedPresentation
APONVIE permanent J-code (J8502) became active April 1, 2026
postoperative nausea and vomitingsource ↗
Mar 2026
▲Enrollment MilestoneCINVANTIApprovedTrial
CINVANTI surpassed 5 million demand units sold since launch
chemotherapy-induced nausea and vomitingsource ↗
Feb 26, 2026
●Quarterly UpdateCorporate
Full-year 2026 net revenue guidance of $173-$183 million and adjusted EBITDA of $10-$20 million issued
Jan 9, 2026
2026
●Quarterly UpdateCorporate
Reaffirmed 2026 full-year guidance: net revenue $173-$183M, Adjusted EBITDA $10-$20M
Jan 2026
▲Timing GuidanceZYNRELEFDiscontinuedPresentation
IGNITE 2.0 program extended through 2026 with 40% increase in target accounts from January 2026
postoperative painsource ↗
2026
▼Timing GuidanceSUSTOLPresentation
Wind-down of SUSTOL by end of 2026
chemotherapy-induced nausea and vomitingsource ↗
2026
●NDA SubmissionZYNRELEFDiscontinuedRegulatory Filing
Expected FDA submission for ZYNRELEF Prefilled Syringe (PFS) in 2026
postoperative painsource ↗
Drug Pipeline Intelligence
C58
Pipeline Score $2.1B
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored13.1x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 911)
Percentile RankHeron Therapeutics, Inc. carries a moderate pipeline score (58/100), with $8.5B risk-adjusted pipeline value, led by HTX-011 in Postoperative Pain (Phase 3), across $69B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HTX-011 Small molecule | Postoperative Pain | Phase 3 | NCT02504580 | 49% | $5.5B | COMPLETED | 1,962 | - | - | Apr 1, 2017 | - | Mar 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZYNRELEF | postpartum pain management in women undergoing Caesarean sections | Phase 2 | 2022-05-16 | pain scores: mild range; opioid free recovery: 27%; opioid rescue medication: 69% less Read More | Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting Read More | |
ZYNRELEF | postpartum pain management in women undergoing Caesarean sections | Phase 2 | 2022-05-16 | pain scores: mild range; opioid free recovery: 27%; opioid rescue medication: 69% less Read More | Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting Read More | |
ZYNRELEF | postpartum pain management in women undergoing Caesarean sections | Phase 2 | 2022-05-16 | pain scores: mild range; opioid free recovery: 27%; opioid rescue medication: 69% less Read More | Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HRTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HRTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HRTX▼ -45.6%on this news
U.S. District Court Issues Decision Regarding CINVANTI Patents — After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal — CARY, N.C.
Heron Therapeutics, Inc. announced that the U.S. District Court for the District of Delaware ruled against its patents for CINVANTI, declaring them invalid. Despite the setback, Heron intends to appeal the decision in hopes of reversal in the United States Court of Appeals for the Federal Circuit. The company emphasizes its commitment to defending its intellectual property rights. This ruling does not affect prior settlement agreements related to CINVANTI or other products.
Read more →HRTX▼ -21%on this news
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF (+27%) and APONVIE (+50%) - Q1 2026
Heron Therapeutics reported its Q1 2026 financial results, highlighting a 32% year-over-year revenue growth in its Acute Care franchise, contributing to a total net revenue of $34.7 million. The company reaffirmed its full-year guidance of $173 to $183 million in net revenue despite a decrease in total revenue compared to the previous year. APONVIE and ZYNRELEF showed strong demand, with notable increases in their revenue contributions. However, a significant decline in CINVANTI revenue and total revenue compared to the previous year raised concerns about market challenges.
Read more →HRTX▲ +11.1%on this news
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - ZYNRELEF and APONVIE Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise - Achieved $154.9 Million in 2025 Net Revenue -
Heron Therapeutics announced their financial results for the fourth quarter and full year of 2025, reporting a 65% growth in net revenue driven by their acute care franchise, particularly ZYNRELEF and APONVIE. They achieved $154.9 million in total net revenue for 2025 and provided optimistic guidance for 2026, anticipating net revenue between $173 million and $183 million. Despite the promising outlook, the oncology franchise faced challenges with a significant revenue decline, raising some concerns about portfolio performance in that area.
Read more →HRTX▲ +9.4%on this news
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth CARY, N.C.
Heron Therapeutics has announced its preliminary unaudited net revenue results for Q4 and full-year 2025, highlighting a strong performance led by ZYNRELEF. The company reported approximately $40.5 million in net revenue for Q4 2025, with ZYNRELEF contributing around $12.5 million to this figure, marking a 35% increase from Q3. In total, Heron generated approximately $154.9 million in net revenue for the year. The company expresses optimism regarding its growth trajectory and ongoing business developments.
Read more →HRTXHeron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress • Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Gu
Heron Therapeutics reported positive financial results for Q3 2025, with total net revenue reaching $38.2 million, an increase of 16.5% year-over-year. Key products like ZYNRELEF and APONVIE demonstrated substantial growth, with respective revenue increases of 49% and 173%. The company reiterated its guidance for 2025, projecting a net revenue range of $153 million to $163 million. Some products, such as SUSTOL and oncology treatments, faced revenue declines, indicating mixed performance across the portfolio.
Read more →HRTXHeron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors CARY, N.C.
Heron Therapeutics has appointed Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of experience in investment management and corporate finance, including his recent role as Managing Director at Starboard Value LP. This appointment follows a Cooperation Agreement with Rubric Capital Management LP. Heron's CEO expressed enthusiasm about Cusack's potential impact on the company's growth and portfolio enhancement.
Read more →HRTXHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics has adopted a Section 382 rights plan to safeguard its net operating loss carryforwards, which amount to approximately $1.37 billion. This plan aims to prevent any single investor from acquiring a significant stake that could limit the company's ability to utilize these tax attributes. The plan is effective as of August 14, 2025, and is part of the company's strategy to enhance cash flow.
Read more →HRTX▼ -28.3%on this news
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Heron Therapeutics has completed a comprehensive capital restructuring aimed at enhancing financial flexibility and reducing total debt. This refinancing will support the company's commercial and development initiatives. The CEO highlighted that this move positions Heron for growth and eliminates near-term debt maturities. The transactions are expected to close on August 12, 2025.
Read more →HRTX▼ -28.3%on this newsshared move
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics reported its Q2 2025 financial results, showcasing a 3.3% increase in total net revenue year-over-year, driven by strong performance in acute care and the APONVIE product line. The company anticipates continued growth, with updated financial guidance suggesting increased net revenue and adjusted EBITDA for the year. However, oncology revenue faced a decline, highlighting challenges in certain product segments.
Read more →HRTX▼ -28.3%on this newsshared move
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics has rescheduled its second quarter 2025 earnings release and conference call to August 8, 2025, at 8:30 a.m. ET. This change allows the company to provide updates on financial results and business highlights. Participants can access the call via phone or webcast, with an archive available for 60 days post-event.
Read more →HRTXHeron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
Heron Therapeutics, Inc. will host a conference call on August 11, 2025, to report its second quarter financial results and discuss recent business highlights. The call will be accessible via phone and webcast, with an archive available for 60 days. The company emphasizes its commitment to improving patient care through innovative therapies.
Read more →HRTX▲ +13.6%on this news
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
Heron Therapeutics has reached a settlement with Mylan Pharmaceuticals to resolve patent litigations concerning CINVANTI and APONVIE. Mylan will be granted a license to market generic versions of these drugs starting June 1, 2032. The settlement follows legal actions initiated by Heron in response to Mylan's attempts to gain FDA approval for generics before the patent expiration in 2035.
Read more →HRTX▲ +13.6%on this newsshared move
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics reported strong financial results for Q1 2025, achieving record adjusted EBITDA. The company highlighted significant revenue growth, particularly for its lead product ZYNRELEF, and announced positive developments such as expanded label indications and partnerships. However, there were declines in certain oncology product revenues, indicating mixed performance across its portfolio.
Read more →HRTXHeron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
Heron Therapeutics has appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025. Hensley, who has over 15 years of experience in various sales and operations roles, previously served as CEO at Veloxis Pharmaceuticals. His extensive background is expected to support Heron's strategic priorities and growth initiatives.
Read more →HRTX▲ +11.4%on this news
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Heron Therapeutics, Inc. has announced plans to report its first quarter 2025 financial results via a conference call on May 6, 2025. The call will take place at 8:00 a.m. ET and will be accessible via phone and webcast. Following the event, an archive will be available on the company's website. The announcement underscores Heron’s focus on advancing healthcare through innovative therapies.
Read more →HRTX▲ +19.9%on this news· ran to +49% by day 3
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics reported strong financial results for Q4 and full-year 2024, achieving positive net income. The company highlighted its operational successes and the promising future of its product ZYNRELEF, which is set for growth due to expanded indications and strategic partnerships. A conference call is scheduled to discuss these results further.
Read more →HRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Heron Therapeutics, Inc. has announced a conference call scheduled for February 27, 2025, to report its fourth quarter and full year 2024 financial results. The call will be accessible via phone and webcast, providing an opportunity to discuss recent developments in the company’s operations. Heron Therapeutics specializes in therapeutic innovations for acute care and oncology patients.
Read more →HRTXHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Heron Therapeutics has announced its relocation of corporate headquarters from San Diego, California, to Cary, North Carolina, effective January 1, 2025. This move will centralize operations and resources, enhancing support for employees and fostering new strategic partnerships. The new headquarters location is situated near the Research Triangle Park, known for its prominent high-tech research community. CEO Craig Collard expressed excitement about this move, viewing it as a new chapter for the company focusing on patient care in acute and oncology settings.
Read more →HRTXHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the...
Heron Therapeutics, Inc. has announced the relocation of its headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. This move aims to centralize operations and support the company's growth in the biotech sector. The new location near the Research Triangle Park is expected to foster strategic partnerships and enhance the company's ability to improve patient care.
Read more →HRTXU.S. District Court Upholds Validity of CINVANTI® Patents
Heron Therapeutics, Inc. reported a positive ruling from the U.S. District Court for the District of Delaware regarding the validity of its CINVANTI patents. The court found that Fresenius Kabi USA, LLC infringed on Heron's patents, thereby allowing Heron to seek a prohibition against Fresenius launching a generic version of CINVANTI until the patents expire in 2035. While the decision is favorable for Heron, it is not final as it may be subject to appeal.
Read more →HRTX▼ -30.4%on this news
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance • Reported positive YTD 2024 Adjusted EBITDA of $1.4 million • Company expects Q4 2024 Net Revenue in the ran
Heron Therapeutics reported its financial results for Q3 2024, revealing a positive Adjusted EBITDA of $1.4 million year-to-date. The company anticipates Q4 2024 net revenue between $37 million and $43 million, indicating strong growth potential. A new Vial Access Needle for ZYNRELEF has been approved and is set to launch in Q4 2024. Additionally, ZYNRELEF's inclusion in the CMS Final Rule Non-Opioid Policy for Pain Relief positions it favorably in the surgical market.
Read more →HRTX▼ -30.4%on this news
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
Heron Therapeutics reported positive financial results for Q3 2024, including a YTD Adjusted EBITDA of $1.4 million. The company anticipates Q4 2024 net revenue between $37 million and $43 million, bolstered by the upcoming launch of ZYNRELEF's new delivery system. However, despite these gains, the company continues to face challenges, including a reported net loss.
Read more →HRTXHeron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Heron Therapeutics has appointed Michael Kaseta to its Board of Directors, enhancing its leadership with his extensive experience in corporate finance and business strategy. Currently CFO and COO at Liquida Corporation, Kaseta has held senior financial roles at Aerami Therapeutics and Aralez Pharmaceuticals, as well as a decade at Sanofi S.A. His appointment is expected to aid Heron in driving growth of its portfolio focused on therapeutic innovations for improving patient care.
Read more →HRTXHeron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of...
Heron Therapeutics has appointed Michael Kaseta to its Board of Directors. Kaseta brings a wealth of experience in corporate finance and biopharma commercialization, having held leadership roles at several companies including Liquidia Corporation and Aerami Therapeutics. CEO Craig Collard expressed confidence in Kaseta's ability to contribute to the company's growth and innovation in therapeutic products.
Read more →HRTX▼ -7.3%on this news
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics, Inc. is set to host a conference call on November 12, 2024, to report its third quarter financial results and discuss recent business highlights. The event will be accessible via phone and webcast, aiming to engage stakeholders. As a commercial-stage biotechnology company, Heron focuses on therapeutic innovations in acute care and oncology. The company emphasizes its commitment to advancing healthcare through its product portfolio.
Read more →HRTXHeron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
Heron Therapeutics (HRTX) has reaffirmed its capability to provide key products, including CINVANTI, SUSTOL, and APONVIE, during a looming shortage of intravenous fluids caused by Hurricane Helene. With a significant supplier's facility closed, the company highlights that its drugs are available in ready-to-administer formats, crucial for continuous patient care. CEO Craig Collard emphasized the importance of these products for managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). Heron is positioned to supply health systems necessitating continuity of care in this critical time.
Read more →HRTXHeron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics has announced that the FDA has approved its Prior Approval Supplement Application for the ZYNRELEF vial access needle (VAN). This new device is designed to simplify the aseptic preparation process and reduce ZYNRELEF's withdrawal time significantly. The VAN is expected to launch in Q4 2024 and aims to facilitate easier use of ZYNRELEF, potentially boosting its adoption for postoperative pain management. The approval is part of a series of recent milestones for ZYNRELEF, aligning with the company's focus on improving patient recovery after surgery.
Read more →HRTX▼ -10.4%on this news
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics has appointed Brett Fleshman as the new Chief Business Officer. Fleshman brings 25 years of experience in corporate strategy and business development, expected to enhance Heron's growth and investor relations efforts. Previously, he held leadership roles in companies such as NovaQuest Capital Management and Veloxis Pharmaceuticals, where he was instrumental in successful acquisition strategies. This appointment aims to drive revenue growth and improve the company's market presence.
Read more →HRTXHeron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023
Heron Therapeutics reported its financial results for the second quarter of 2024, showing an increase in net product sales to $36.0 million, up from $31.8 million in the same period last year. The company has narrowed its financial guidance, projecting adjusted operating expenses between $107.0 million and $111.0 million. A significant development includes a set PDUFA goal date of September 23, 2024, for the ZYNRELEF Vial Access Needle. Heron is also moving forward with expanding the capabilities of ZYNRELEF and enhancing its sales force through training.
Read more →HRTXHeron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
Heron Therapeutics reported a 13.8% increase in net product sales for Q2 2024, totaling $36.0 million. The company narrowed its financial guidance, indicating improved operational efficiency. ZYNRELEF's PDUFA goal date is set for September 23, 2024, and it has been included in the proposed 2025 NOPAIN Act. However, the company continues to face a net loss of $9.2 million.
Read more →HRTXHeron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
Heron Therapeutics, Inc. has announced it will report its second quarter 2024 financial results on August 6, 2024. The company will host a conference call and live webcast at 4:30 p.m. ET to discuss these results and recent business highlights. Additionally, details regarding accessing the call and the availability of an archive for 60 days post-call were provided. Heron continues to focus on therapeutic innovations aimed at enhancing patient care in oncology.
Read more →HRTXHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
Heron Therapeutics announced that ZYNRELEF will be included in the proposed 2025 Non-Opioid Policy for Pain Relief by CMS. This inclusion is set to take effect on April 1, 2025, allowing for continued reimbursement under the outpatient and ambulatory surgical center payment systems. The move is expected to further non-opioid pain management access and potentially reduce opioid dependence post-surgery. Heron anticipates that the favorable policy changes will influence commercial payer reimbursement decisions as well.
Read more →HRTX▼ -21%on this news
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA...
Heron Therapeutics announced that the FDA has accepted its Prior Approval Supplement application for ZYNRELEF's new Vial Access Needle (VAN). The FDA set a PDUFA goal date of September 23, 2024, for the review. The VAN aims to simplify the preparation process and reduce withdrawal time significantly. The company is also progressing with its partnership with CrossLink to promote ZYNRELEF.
Read more →HRTX▼ -21%on this news
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle (“VAN”) -The U.S. Food and Drug Administration (“FDA”) assigned a Prescript
Heron Therapeutics announced that the FDA accepted its application for the Prior Approval Supplement for the ZYNRELEF Vial Access Needle, with a PDUFA goal date of September 23, 2024. If approved, the VAN aims to simplify aseptic preparation and reduce withdrawal time from ZYNRELEF significantly. The company is also advancing its partnership with CrossLink Life Sciences to promote ZYNRELEF, which is expected to enhance its adoption among orthopedic surgeons. The VAN could be available by the fourth quarter of this year, marking an important development for the product's market presence.
Read more →HRTXHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval...
Heron Therapeutics has submitted a Prior Approval Supplement to the FDA for ZYNRELEF's Vial Access Needle (VAN), aiming to enhance the drug's preparation process. The VAN could reduce withdrawal time significantly compared to the current method. ZYNRELEF, which has shown superior efficacy in postoperative pain management, awaits FDA review, expected within 4 to 6 months.
Read more →HRTXHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle (“VAN”)
Heron Therapeutics announced its submission of a Prior Approval Supplement to the FDA for the Vial Access Needle (VAN) to be used with ZYNRELEF. The VAN aims to enhance the preparation process, reducing the time for product withdrawal significantly. If approved, it is expected to improve adoption of ZYNRELEF and ultimately aid in postoperative pain management. Alongside these advancements, the company acknowledges the ongoing risks related to FDA approval and the medication's associated safety concerns.
Read more →HRTXHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net L
Heron Therapeutics reported its first-quarter financial results for 2024, highlighting a significant increase in net product sales to $34.7 million, up from $29.6 million in the previous year. The company experienced a notable improvement in gross margins, which rose to 76%. Additionally, it announced the FDA's approval of an expanded indication for its product ZYNRELEF and plans to host its first Investor Day event. Heron also provided financial guidance, expecting product revenues between $138 million and $158 million for the year.
Read more →HRTXHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from...
Heron Therapeutics reported a strong financial performance for Q1 2024, with net product sales rising to $34.7 million and a gross margin of 76%. The FDA approved an expanded indication for ZYNRELEF, which is expected to boost its market presence. The company is also integrating CrossLink Life Sciences for promotional efforts. Despite improvements, Heron still faces challenges with ongoing losses and high operating expenses.
Read more →HRTX▼ -5.4%on this news
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics, Inc. has announced a conference call and live webcast to discuss its first quarter 2024 financial results, scheduled for May 7, 2024. The company is focused on developing therapeutic innovations aimed at improving medical care for patients. An archive of the call will be available on its website for 60 days following the event. This announcement aligns with their commitment to transparency and investor engagement.
Read more →HRTX▲ +7.7%on this news
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics, Inc. has announced it will host an Investor Day on May 15, 2024, in New York City. This event will showcase the company's renewed focus on its Acute Care and Oncology franchises through presentations and discussions featuring patient and physician experiences. Additionally, updates on ongoing initiatives meant to amplify the reach and adoption of the company's commercial products will be shared. A live webcast of the event will be provided for those unable to attend in person.
Read more →HRTXHeron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. has announced that CEO Craig Collard will participate in a fireside chat during the 23rd Annual Needham Virtual Healthcare Conference, which takes place from April 8-11, 2024. The event will be accessible through a live webcast on the company's website. This participation underscores Heron's focus on therapeutic innovations aimed at enhancing patient care in healthcare and oncology.
Read more →HRTXHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • 2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance
Heron Therapeutics reported strong financial results for Q4 and full-year 2023, with oncology care franchise revenue surpassing guidance at $107.9 million. ZYNRELEF set a quarterly sales record of $5.6 million and received FDA approval for an expanded indication, allowing for increased market access. Additionally, the company ended the year with $80.4 million in cash and established a partnership aimed at enhancing the promotion of ZYNRELEF. The outlook for 2024 remains optimistic with reaffirmed guidance for product revenues in the range of $138.0 to $158.0 million.
Read more →HRTXHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for...
Heron Therapeutics reported strong financial results for Q4 and full-year 2023, with oncology care franchise revenue reaching $107.9 million. The company achieved record net product sales of $5.6 million for ZYNRELEF in Q4 and announced a partnership to boost its promotional efforts. Additionally, Heron received FDA approval for an expanded indication of ZYNRELEF, enhancing its market opportunities. Despite these successes, the company reported a net loss and increased liabilities.
Read more →HRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Heron Therapeutics, Inc. has scheduled a conference call for March 12, 2024, to report its fourth quarter and full year 2023 financial results. The call will discuss recent business highlights and can be accessed by both U.S. and international participants. The company aims to improve patient care through its innovative drug development pipeline. An archive of the call will be available on their website for 60 days following the event.
Read more →HRTX▼ -6%on this news
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures Expanded indication for ZYNRELEF now covers approximately 13 million procedures annua
Heron Therapeutics has announced the FDA's approval for a supplemental New Drug Application for ZYNRELEF, now expanding its indication to include a broader range of orthopedic and soft tissue surgical procedures. This expansion significantly increases the potential annual usage of ZYNRELEF, which is now applicable for approximately 13 million procedures. The approval follows successful studies demonstrating ZYNRELEF's effectiveness in managing postoperative pain without significant safety concerns. This milestone is expected to enhance pain management for patients undergoing various surgeries, aligning with Heron's commitment to addressing unmet medical needs.
Read more →HRTX▼ -6%on this news
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the...
Heron Therapeutics has received FDA approval to expand the indication for ZYNRELEF, allowing its use in additional orthopedic and soft tissue surgical procedures. This expansion is expected to cover approximately 13 million procedures annually, significantly increasing its market potential. The approval follows successful clinical trials with no new safety concerns identified.
Read more →HRTX▲ +18.1%on this news
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF , the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
Heron Therapeutics has entered a five-year distribution partnership with CrossLink Life Sciences to enhance the promotional efforts for ZYNRELEF, a non-opioid dual-acting local anesthetic designed for post-operative pain management. This collaboration will see an increase of approximately 650 sales representatives in Heron's network, initially on a regional basis before a nationwide rollout. Although the partnership aims to provide greater access to ZYNRELEF for orthopedic surgical patients, uncertainties remain regarding the market's reception and the timing of regulatory approvals for expanded indications.
Read more →HRTX▲ +18.1%on this news
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor...
Heron Therapeutics has partnered with CrossLink Life Sciences to enhance the promotion of ZYNRELEF, a non-opioid local anesthetic for post-operative pain. This five-year partnership aims to expand the sales network, initially regionally and then nationally, adding around 650 representatives. ZYNRELEF has shown significant benefits in reducing post-surgical pain and opioid use, with an upcoming FDA review for expanded indications.
Read more →HRTXHeron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior ...
Heron Therapeutics reported a positive update for Q3 2023, increasing its net product sales guidance for the oncology care franchise to $104-$106 million. The company anticipates full-year 2023 net product sales to reach $123-$125 million and projects growth in 2024. Despite a loss of $24.9 million for the quarter, Heron is optimistic about its path to profitability and has implemented a cost reduction plan.
Read more →HRTXHeron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance • Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 m
Heron Therapeutics has announced its third-quarter financial results for 2023, revealing an increase in net product sales guidance for its oncology care franchise to a range of $104 million to $106 million. The overall net product sales are projected to be between $123 million and $125 million for the year, with significant improvements anticipated in EBITDA and gross margin through 2024. Despite some operational losses and inventory write-offs, Heron is optimistic about its growth trajectory and has implemented a cost reduction plan to enhance financial stability.
Read more →HRTX▲ +6.9%on this news· ran to -21% by day 3
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
Heron Therapeutics, Inc. announced that it will report its third quarter 2023 financial results on November 14, 2023. The company will host a conference call at 4:30 p.m. ET to discuss these results along with recent business highlights. This event will be accessible via phone and webcast, with an archive available for 60 days. Heron is focused on developing therapies that meet significant patient needs and has a range of products in its portfolio.
Read more →HRTX▼ -6.8%on this news
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...
Heron Therapeutics announced its Q2 2023 financial results, highlighting a strong capital position after securing a $50 million credit facility and a $30 million equity raise. The company reported increased product sales in both its acute care and oncology care franchises, while also noting a favorable outcome in ongoing patent litigation for CINVANTI. Despite these positives, Heron continues to face significant operational losses.
Read more →HRTX▼ -6.8%on this news
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates • Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equi
Heron Therapeutics reported its financial results for Q2 2023, highlighting favorable developments including a $50 million credit facility and a $30 million equity raise. The new management team announced a $75 million cost reduction program aimed at optimizing the company's operations. Additionally, the company reiterated its guidance for oncology care franchise net product sales between $99 million and $103 million for the year, although approval for ZYNRELEF has been delayed by three months due to FDA review.
Read more →HRTXHeron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Heron Therapeutics, Inc. will host a conference call on August 14, 2023, to report its second quarter 2023 financial results and discuss recent business highlights. The call can be accessed by phone or through a live webcast, with an archive available for later viewing. The company emphasizes its commitment to developing innovative treatments for unmet patient needs. Heron cautions that its statements about future expectations are subject to risks and uncertainties.
Read more →HRTX▲ +11.6%on this news
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
Heron Therapeutics, Inc. announced a cost reduction plan and corporate restructuring aimed at achieving $75 million in cash savings by 2025. The new executive management team will focus on streamlining operations and optimizing product value, with an aim for profitability by late 2024. The restructuring includes a 25% reduction in the workforce, which will incur non-recurring expenses. The company believes these changes, along with a concurrent $30 million equity financing, will enhance its commercial capabilities.
Read more →HRTX▲ +11.6%on this news
Heron Therapeutics Announces $30 Million Private Placement Financing Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...
Heron Therapeutics has announced a private placement financing agreement to raise approximately $30 million by selling shares to institutional investors. The deal is led by Rubric Capital Management and includes other investors. The funds will be used for working capital and general corporate purposes, with the transaction expected to close soon, pending customary conditions.
Read more →HRTX▲ +11.6%on this news
Heron Therapeutics Announces $30 Million Private Placement Financing
Heron Therapeutics announced a $30 million private placement financing to strengthen its capital for ongoing operations. Led by Rubric Capital Management, the placement involves existing and new institutional investors purchasing over 20 million shares. The proceeds are intended for working capital and general corporate uses, although the shares are unregistered, which may pose some restrictions. The closing of this deal is anticipated to occur shortly, subject to standard conditions.
Read more →HRTXHeron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
Heron Therapeutics, Inc. has announced the appointment of Ira Duarte as Chief Financial Officer, bringing over 25 years of finance experience, including roles in the pharma industry. Ms. Duarte's immediate focus will be on improving operational efficacy and reducing cash burn while maximizing the potential of Heron's commercial portfolio. Heron has established itself as a commercial-stage biotechnology company that is dedicated to bettering patient lives through innovative treatments, particularly in the post-operative pain and oncology sectors.
Read more →HRTXHeron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
Heron Therapeutics has announced the appointment of William Forbes, Pharm.D., as its new Chief Development Officer, succeeding Kimberly Manhard. Forbes brings extensive experience with a track record of 14 marketing approvals across various therapeutic areas. He will oversee the clinical and product development efforts for Heron's acute care and oncology franchises. His appointment is considered a strategic move to bolster Heron's capabilities in addressing unmet needs in these areas.
Read more →HRTX▼ -9%on this news· ran to -49% by day 3
Heron Therapeutics Announces Financial Results for the Three Months Ended
Heron Therapeutics released its financial results for the first quarter of 2023, showing a 26% increase in net product sales to $29.6 million compared to the same period in 2022. This growth was driven primarily by their oncology care franchise. The company appointed Craig Collard as CEO and Jason Grillot as VP of Sales and Marketing, focusing on enhancing current product value and efficiency. While there was a reduction in operational expenses, net losses persisted due to increased operational costs and litigation fees.
Read more →HRTXHeron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Heron Therapeutics, Inc. has announced it will host a conference call on May 11, 2023, to discuss its first quarter financial results and recent business highlights. The call will be accessible via teleconference and a live webcast, and an archive will be available for 60 days following the event. Heron emphasizes its commitment to addressing unmet patient needs through innovative drug development and advanced technologies. However, the company advises that its future projections include inherent risks and uncertainties.
Read more →HRTX▼ -5.6%on this news
Heron Therapeutics Announces Commercial Leadership Changes
Heron Therapeutics has announced a shift in its commercial leadership team, appointing Jason Grillot as Vice President of Sales and Marketing for Acute Care, effective April 24, 2023. The move comes as John Poyhonen and Michael Mathews will leave the company by April 30, 2023. CEO Craig Collard will take charge of the commercial organization during this transition. Grillot aims to advance Heron’s acute care offerings, particularly focusing on their products ZYNRELEF and APONVIE.
Read more →HRTX▲ +17.9%on this news· ran to +51% by day 3
Heron Therapeutics Announces New CEO and Board Chairman Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board
Heron Therapeutics has appointed Craig Collard as the new CEO, succeeding Barry Quart, who has stepped down. The company has also announced Adam Morgan as the new Chairman of the Board. Collard, who has extensive experience in leading pharmaceutical companies through strategic changes, expressed confidence in Heron's ability to deliver value to stakeholders. The restructure is part of a commitment to strong corporate governance, separating the roles of CEO and Chairman.
Read more →HRTXHeron Therapeutics Announces Financial Results for the Three and Twelve Months Ended
Heron Therapeutics, Inc. reported a 25% increase in annual net product sales, reaching $107.7 million for 2022. The company launched APONVIE in March 2023 and experienced significant growth in sales for its products ZYNRELEF and CINVANTI. Despite these positive developments, Heron also reported a substantial net loss of $19.9 million in Q4 2022, along with a notable decrease in cash reserves and a reduction in headcount to alleviate financial strains. This highlights both achievements and challenges faced by the company as it navigates the biopharmaceutical landscape.
Read more →HRTX▲ +11.1%on this news
Forward-looking Statements This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on man
Heron Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through payment status for APONVIE, effective April 1, 2023. This designation will allow Medicare reimbursement for the drug, which is aimed at preventing postoperative nausea and vomiting (PONV), in hospital outpatient departments and ambulatory surgical centers. The move is expected to improve patient access and streamline billing processes, enhancing the drug's market potential. APONVIE, recently launched and FDA-approved, is positioned as a preferred treatment for patients at risk of PONV.
Read more →HRTX▲ +11.1%on this news
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
Heron Therapeutics announced that the CMS has granted transitional pass-through payment status for its newly launched drug, APONVIE (aprepitant), effective April 1, 2023. This status allows APONVIE to be reimbursed separately outside the surgical bundle payment in hospital outpatient departments and ambulatory surgical centers. With this approval, APONVIE enhances patient access to treatment for postoperative nausea and vomiting, a significant need in outpatient surgical settings. The approval shortly after the drug's launch highlights early momentum in its commercial journey.
Read more →HRTX▼ -5.7%on this newsshared move
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
Heron Therapeutics, Inc. has announced a conference call and webcast scheduled for March 23, 2023, to discuss its financial results for the fourth quarter and full year of 2022. The event will highlight the company's recent business developments. Heron is dedicated to improving patient outcomes through innovative treatments for unmet medical needs in acute care and oncology. The event will be accessible to both domestic and international audiences.
Read more →HRTXHeron Therapeutics Announces U.S. Commercial Launch of APONVIE TM for the Management of Postoperative Nausea and Vomiting in Adults - APONVIE, the first and only intravenous (IV) formulation of a substance P/neurokinin-1
Heron Therapeutics has announced the U.S. commercial launch of APONVIE, an intravenous formulation for preventing postoperative nausea and vomiting in adults. APONVIE is delivered via a single IV push, achieving therapeutic levels quickly and offering protection for up to 48 hours. The company expects substantial sales opportunities, leveraging its existing acute care commercial teams without additional costs for the launch. This innovative product aims to enhance patient outcomes post-surgery, addressing a common complication after procedures.
Read more →HRTXHeron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference
Heron Therapeutics, Inc. announced its participation in a fireside chat at the 43rd Annual Cowen Healthcare Conference, scheduled for March 7, 2023, in Boston, MA. The event aims to highlight the company's commitment to developing advanced treatments to meet significant patient needs. A live webcast will be accessible through the company's website, providing an avenue for wider audience engagement. This participation underscores Heron's role in the biotech industry, showcasing its portfolio designed to improve patient care.
Read more →HRTX▲ +10.9%on this newsshared move
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital Appoints Three New Independent Directors
Heron Therapeutics has entered into a cooperation agreement with shareholders Rubric Capital and Velan Capital, resulting in the appointment of three new independent directors to its Board. This move is part of Heron's ongoing Board refreshment process, which aims to drive shareholder value and improve the company's governance. The company also plans to separate the roles of Chairman and CEO after its 2023 Annual Meeting, suggesting a strategic shift towards enhanced operational oversight. Heron remains optimistic about its product growth in the acute care and oncology sectors.
Read more →HRTXHeron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021
Heron Therapeutics has reported a 24% increase in preliminary annual net product sales for 2022, amounting to $106.7 million, compared to the previous year. The fourth-quarter sales for ZYNRELEF surged by 40%, contributing significantly to the overall growth. Heron has also submitted a supplemental New Drug Application for ZYNRELEF to expand its indications and successfully launched its fourth product, APONVIE, approved for postoperative nausea and vomiting. The company projects further growth in its oncology care franchise for 2023, with anticipated sales between $99 million and $103 million.
Read more →HRTX▲ +9.8%on this news
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRE
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF - Supplemental New Drug Application Submitted Requestin
Read more →HRTXHeron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference
SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Financial Results for the Three and Nine Months Ended
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates - APONVIE approval by FDA, U.S. launch planned for Q1 2023 - - ZYNRELEF unit demand grew 18% over prior quarter in Q3 2022 - - Oncology
Read more →HRTXHeron Therapeutics Announces U.S. FDA Approval of APONVIE TM (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokin
Heron Therapeutics Announces U.S. FDA Approval of APONVIETM (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for PONV - - Deliv
Read more →HRTX▲ +15.1%on this news· ran to +48% by day 3
Heron Therapeutics Announces $76.5 Million Private Placement Financing
SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has en
Read more →HRTX▲ +15.1%on this news· ran to +48% by day 3
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates - ZYNRELEF launch trend continues at a strong pace with sequential quarterly product sales increase of 140% and unit demand increase of 47% -
Read more →HRTXHeron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the compa
Read more →HRTX▼ -12%on this news
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend - - Reduces organization headcount by 34% - - Priorities remain on commercial growth for both the Acute Care and Oncology Care franchises - SAN DIEGO,
Read more →HRTXHeron Therapeutics Announces Publication Showing ZYNRELEF as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty
Heron Therapeutics Announces Publication Showing ZYNRELEF as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty SAN DIEGO, June 14, 2022 /PRNewswire/ -- Heron Therapeutics, I
Read more →HRTXHeron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
SAN DIEGO, May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that company m
Read more →HRTXHeron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting
- New interim data from Phase 2 study suggests ZYNRELEF was well-tolerated and may effectively manage postpartum pain and minimize postoperative opioid use in women undergoing Caesarean sections - SAN DIEGO, May 16, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a
Read more →HRTXHeron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
SAN DIEGO, May 3, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th
Read more →HRTXHeron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference
SAN DIEGO, April 5, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Secures Pass-through Payment Status for ZYNRELEF from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care - ZYNRELEF is the only loca
Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care - ZYNRELEF is the only local anesthetic with separate reimbursement in both the Hospit
Read more →HRTX▲ +7%on this news
Heron Therapeutics Announces Approval of ZYNRELEF by Health Canada for the Management of Postoperative Pain - ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada
Heron Therapeutics Announces Approval of ZYNRELEF by Health Canada for the Management of Postoperative Pain - ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada - SAN DIEGO, Mar. 17, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq:
Read more →HRTXHeron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTX▲ +11.4%on this news
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF - Approval provides a significantly broader indication for ZYNRELEF, now covering approximately 7 million procedures a year - -
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF - Approval provides a significantly broader indication for ZYNRELEF, now covering approximately 7 million procedures a year - - Conference call and webcast today, December 9, 2021 at 8:
Read more →HRTXHeron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of pati
Read more →HRTXHeron Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF Indication Statement Based on Successful Outcome of FDA Type C Meeting - FDA agreed to the immediate filing
Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF Indication Statement Based on Successful Outcome of FDA Type C Meeting - FDA agreed to the immediate filing of supplemental NDA to significantly expand the ZYNRELEF i
Read more →HRTXHeron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery
SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours
SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced Z
Read more →HRTXHeron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference
SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Announces $150 Million Convertible Debt Financing
SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissory notes (the "Notes") in a private placement transaction. The Notes are convertible into shares of Hero
Read more →HRTXHeron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
SAN DIEGO, May 13, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXThis presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and as
Approval May 13, 2021 Exhibit 99.2 This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the da
Read more →HRTXHeron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery - 77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids to Manage Their
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery - 77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 Hours After Surgery and Cont
Read more →HRTXHeron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program - Preliminary Full-Year 2020 Net Product Sales for CINV Franchise of Approximately $88.3 Million, versus
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program - Preliminary Full-Year 2020 Net Product Sales for CINV Franchise of Approximately $88.3 Million, versus Guidance of $85 Million - - Full-Year 2021 Net Product Sa
Read more →HRTXHeron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by d
Read more →HRTXHeron Therapeutics Receives European Commission Authorization for ZYNRELEF TM (HTX-011) for the Treatment of Postoperative Pain
Heron Therapeutics Receives European Commission Authorization for ZYNRELEFTM (HTX-011) for the Treatment of Postoperative Pain SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the liv
Read more →HRTXHeron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery - Over 90% of Hernia Repair Patients Receiving HTX-011 Required N
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery - Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hou
Read more →HRTXHeron Therapeutics to Present at Cantor Virtual Global Healthcare Conference
SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the l
Read more →HRTXHeron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF (HTX-011) for the Management of Postoperative Pain
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF (HTX-011) for the Management of Postoperative Pain SAN DIEGO, July 24, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients
Read more →HRTXHeron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI for the Treatment of COVID-19
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI for the Treatment of COVID-19 SAN DIEGO, July 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by d
Read more →HRTXHeron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain - Complete Response Letter Requests Additional Non-Clinical Information - - No Clinical Safety or Efficacy Issues
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain - Complete Response Letter Requests Additional Non-Clinical Information - - No Clinical Safety or Efficacy Issues and No Chemistry, Manufacturing and Controls (CMC) - Conf
Read more →HRTXAbout Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important
Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty SAN DIEGO, June 4, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on im
Read more →HRTXHeron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty
SAN DIEGO, June 4, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain SAN DIEGO, May 18, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of pat
Read more →HRTXHeron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 9, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Present at the 40th Annual Cowen Healthcare Conference
SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain - Updated Prescription Drug User Fee Act (PDUFA) Goal Date Is
Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain - Updated Prescription Drug User Fee Act (PDUFA) Goal Date Is June 26, 2020 - - Contract Manufacturing Site for HTX-011 Reinspected by FDA with No Observati
Read more →HRTXHeron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Highlights Progress in Pain Management and CINV Franchises
SAN DIEGO, Jan. 13, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighte
Read more →HRTXHeron Therapeutics Highlights Progress in Pain Management and CINV Franchises - Marketing Applications for HTX-011 for Postoperative Pain Management Are under Review in the United States, the European Union and Canada -
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises - Marketing Applications for HTX-011 for Postoperative Pain Management Are under Review in the United States, the European Union and Canada - - Preliminary Fourth-Quarter 2019 Net Product Sales for CI
Read more →HRTXHeron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a D ual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain SAN DIEGO, Calif. -- (PR NEWSWIRE)
Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain SAN DIEGO, Calif. -- (PR NEWSWIRE) - December 16, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commerci
Read more →HRTXHealth Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain SAN DIEGO, Calif. -- (PR NEWSWIRE)
Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain SAN DIEGO, Calif. -- (PR NEWSWIRE) - December 3, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company foc
Read more →HRTXHeron Therapeutics to Present at the Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Present at the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Present at the Stifel 2019 Healthcare Conference
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain - FDA Sets Prescription Drug User Fee Act ( PDUFA) Goal Date of
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain - FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of March 26, 2020 - SAN DIEGO, Calif. -- (PR NEWSWIRE) - October 28, 2019 -- Heron Thera
Read more →HRTXForward-looking Statements This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on m
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC) SAN DIEGO, Calif. -- (PR NEWSWIRE) - October 22, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a
Read more →HRTXHeron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today a
Read more →HRTXHeron Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today a
Read more →HRTXHeron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty
SAN DIEGO, Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced p
Read more →HRTXHeron Therapeutics Appoints Kimberly Manhard to Board of Directors
SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Appoints Stephen Davis to Board of Directors
SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain
SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXAbout Heron Therapeutics, Inc. Heron Therapeutics , Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain SAN DIEGO, Calif. -- (PR NEWSWIRE) - October 1, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives
Read more →HRTXexcept as may be required by law. Investor Relations and Media Contact: David Szekeres Senior VP, General Counsel, Business Development and Corporate Secretary Heron Therapeutics, Inc. dszekeres@herontx.com 858-251-4447
Heron Therapeutics Appoints Stephen Davis to Board of Directors SAN DIEGO, Calif. -- (PR NEWSWIRE) - October 1, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm
Read more →HRTXstatements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: David Szekeres Senior
Heron Therapeutics Appoints Kimberly Manhard to Board of Directors SAN DIEGO, Calif. -- (PR NEWSWIRE) - October 1, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class tre
Read more →HRTXHeron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery SAN DIEGO, Calif. - (PR NEWSWIRE)
Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery SAN DIEGO, Calif. - (PR NEWSWIRE) - August 20, 2019 -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focu
Read more →HRTXHeron Therapeutics to Present at 2019 JMP Securities Life Sciences Conference
SAN DIEGO, June 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Present at Jefferies 2019 Healthcare Conference
SAN DIEGO, May 29, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy SAN DIEGO, Calif. (PR NEWSWIRE)
Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy Calif. (PR NEWSWIRE) May 21, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of pa
Read more →HRTXHeron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen SAN DIEGO, Calif. (PR NEWSWIRE)
Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen SAN DIEGO, Calif. (PR NEWSWIRE) May 14, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a com
Read more →HRTXHeron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th
Read more →HRTXHeron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th
Read more →HRTXHERON THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FOR HTX-011 FOR THE MANAGEMENT OF POSTOPERATIVE PAIN - Complete Response Letter Requests Additional Chemistry Manufacturing and Controls (CMC) and Non-Clinical Informa
HERON THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FOR HTX-011 FOR THE MANAGEMENT OF POSTOPERATIVE PAIN - Complete Response Letter Requests Additional Chemistry Manufacturing and Controls (CMC) and Non-Clinical Information - - No Clinical Safety or Efficacy Issues Identifie
Read more →HRTXHeron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management SAN DIEGO, Calif. (PR NEWSWIRE)
Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management SAN DIEGO, Calif. (PR NEWSWIRE) April 1, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on
Read more →HRTX77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
SAN DIEGO, March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXof Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy - Bunionectomy Results Complement Opioid-Free Result
77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in Multi-center Postoperative Pain Management Study in Bunionectomy - Bunionectomy Results Complement Opioid-Free Results from the Previously Reported Hernia Repair Study - S
Read more →HRTXHeron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
SAN DIEGO, March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that B
Read more →HRTXHeron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI Label for IV Push SAN DIEGO, Calif. (PR NEWSWIRE)
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI Label for IV Push SAN DIEGO, Calif. (PR NEWSWIRE) February 26, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients
Read more →HRTXHeron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that B
Read more →HRTXHeron Therapeutics Announces Retirement of Robert Rosen as President
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced t
Read more →HRTXHeron Therapeutics Highlights Progress in Pain Management and CINV Franchises - Acceptance of HTX-011 NDA for Postoperative Pain Management with Priority Review Designation; PDUFA Date of
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises - Acceptance of HTX-011 NDA for Postoperative Pain Management with Priority Review Designation; PDUFA Date of April 30, 2019 - - 90% of Patients Treated with HTX-011 Opioid-Free 72 Hours Post-Surger
Read more →HRTXof Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study SAN DIEGO, Calif. (PR NEWSWIRE)
90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study SAN DIEGO, Calif. (PR NEWSWIRE) January 3, 2019 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology c
Read more →HRTX90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced r
Read more →HRTXFDA Grants Priority Review Designation for Heron Therapeutics NDA for HTX-011, a Non-Opioid for Postoperative Pain Management - FDA Assigned PDUFA Goal Date of
FDA Grants Priority Review Designation for Heron Therapeutics NDA for HTX-011, a Non-Opioid for Postoperative Pain Management - FDA Assigned PDUFA Goal Date of April 30, 2019 - - FDA Not Currently Planning Advisory Committee Meeting for NDA - SAN DIEGO, Calif. (PR NEWSWIRE) D
Read more →HRTXHeron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that B
Read more →HRTXU.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a f
Read more →HRTXHeron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
Read more →HRTXHeron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that
Read more →HRTXHeron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation -HTX-011 Significantly Reduced Both Pain Intensity and Opioid Use in Patients Undergoi
Heron Announces Positive Topline Results from Phase 2b Clinical Studies of Total Knee Arthroplasty and Breast Augmentation -HTX-011 Significantly Reduced Both Pain Intensity and Opioid Use in Patients Undergoing Total Knee Arthroplasty- -HTX-011, Administered via Either Insti
Read more →HRTXHERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR - HTX-011 Achieved All Primary and Key Secondary Endpoints- -HTX-011 Produced Statistically Signi
HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR Achieved All Primary and Key Secondary Endpoints- -HTX-011 Produced Statistically Significant Reductions in Both Pain Intensity and Need for Opioids throu
Read more →HRTXHeron Therapeutics Highlights Progress in CINV and Pain Management Franchises - SUSTOL Fourth-Quarter 2017 Net Sales of Approximately $10 Million, Up 16% from Third-Quarter 2017 Net Sales of $8.6 Million; Full-Year 2017
Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises - SUSTOL Fourth-Quarter 2017 Net Sales of Approximately $10 Million, Up 16% from Third-Quarter 2017 Net Sales of $8.6 Million; Full-Year 2017 Net Sales of Approximately $31 Million, versus Guidance of
Read more →HRTXHeron Therapeutics Announces U.S. FDA Approval of CINVANTI TM (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) - CINVANTI Is the First and Only Poly
Heron Therapeutics Announces U.S. FDA Approval of CINVANTITM (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) - CINVANTI Is the First and Only Polysorbate 80-Free, Intravenous Formulation of an NK1 Receptor
Read more →HRTXHeron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA -Phase 3 Program Expected to Enable Broad Indication- -NDA Filing Planned
Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting -Phase 3 Program Expected to Enable Broad Indication- -NDA Filing Planned for 2018- 2 Results Demonstrate Clear Superiority to Bupivacaine
Read more →HRTXHERON THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF HTX-011 IN ABDOMINOPLASTY - HTX-011 produced statistically significant reductions in both pain intensity and need for opioids following
HERON THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF HTX-011 IN ABDOMINOPLASTY statistically significant reductions in both pain intensity and need for opioids following abdominoplasty (tummy tuck) through 96 hours post-surgery - - Results confir
Read more →HRTXHeron Therapeutics Announces U.S. FDA Approval of SUSTOL (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting SUSTOL is the first extended-release 5-HT3 receptor antagon
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting REDWOOD CITY, Calif. August 10, 2016 Heron Therapeutics, Inc. (NASDAQ: HRTX), today announced that the U.S. Food and
Read more →HRTXHeron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain -Statistically and clinically significant reductions in pain intensity through 96 hours after bun
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of -Statistically and clinically significant reductions in pain intensity through 96 hours after bunion surgery and through 48 hours after hernia surgery -Increase in time to fi
Read more →HRTXLegal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including unc
Company Update January 11, 2016 Exhibit Legal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associa
Read more →HRTXHeron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain -Pain intensity through 24 hours reduced by 69% -Pain intensity through 72 hours reduced by 40%
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of -Pain intensity through 24 hours reduced by 69% -Pain intensity through 72 hours reduced by 40% -Time to first use of opiate rescue medication increased by 488% -32% of pat
Read more →HRTXHeron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL -Primary endpoint achieved -SUSTOL, as part of a three-drug regimen, is the first 5-HT 3 antagonist to demonstrate superiority to standard-
Heron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL -Primary endpoint achieved -SUSTOL, as part of a three-drug regimen, is the first 5-HT3 antagonist to demonstrate superiority to standard-of-care for delayed nausea and vomiting after HEC -SUST
Read more →HRTXLegal Disclaimer This presentation contains forward looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward looking statements involve risks and uncertainties, including uncer
Evaluate Pharma 52 Financial Summary Summary Statement of Operations (In thousands, except per share data) Three Months Ended March 31, 2015 Revenue $ Operating expenses 20,360 Other income (expenses) (210) Net loss $ (20,570) Net loss per share 1 $ (0.70) Condensed Balance Sheet
Read more →HRTXHeron Therapeutics Reports Positive Results from Phase 1 Study of HTX-011 -Results Support Best-in-Class Potential for Lead Candidate for Post-Operative Pain
Heron Therapeutics Reports Positive Results from Phase 1 Study of HTX-011 -Results Support Best-in-Class Potential for Lead Candidate for Post-Operative Pain REDWOOD CITY, Calif. March 19, 2015 Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company, announced today po
Read more →HRTXHeron Therapeutics Provides Update on SUSTOL Program - SUSTOL Phase 3 study in delayed-HEC patients progressing rapidly over 100 site locations opened in first two months - Based on faster than expected start-up, Heron n
Heron Therapeutics Provides Update on SUSTOL Program - SUSTOL Phase 3 study in delayed-HEC patients progressing rapidly over 100 site locations opened in first two months - Based on faster than expected start-up, Heron now plans to include delayed-HEC results in NDA resubmissio
Read more →HRTXHeron Therapeutics Reports Positive Results for Post-Surgical Pain Program - Advanced Biochronomer combination product formulation HTX-011 demonstrates significantly reduced pain compared to Exparel for up to 72 hours po
Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program REDWOOD CITY, Calif. May 14, 2014 Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced that it has selected HTX-011, a unique combination product utilizing its pro
Read more →HRTXHeron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress
Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress REDWOOD CITY, Calif. March 5, 2014 Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported fourth quarter and full year
Read more →HRTXHeron Therapeutics, Inc. All rights reserved. Confidential. 2 Legal Disclaimer This presentation contains forward looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward looki
J Otaryngol Head Neck Surg 2008; 37(6): 836 43; 8 Ivani G, et al. Can J Anaesth 1999; 46(5): 467 469; 9 Pitimana aree S, et al. Reg Anesth Pain Med 2005; 30(5): 446 51; http://www.naropin us.com/about_benefits.php 2 Source: KOL interviews October 2013 Notes 1 1 2 3 7 5 KOL Feedba
Read more →HRTXA.P. Pharma Announces Third Quarter 2013 Financial Results and Highlights Recent Corporate Progress
A.P. Pharma Announces Third Quarter 2013 Financial Results and Highlights Recent Corporate Progress REDWOOD CITY, Calif. November 12, 2013 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended September 30
Read more →HRTXA.P. Pharma Announces Second Quarter 2013 Financial Results and Highlights Recent Corporate Progress
A.P. Pharma Announces Second Quarter 2013 Financial Results and Highlights Recent REDWOOD CITY, Calif. August 8, 2013 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended June 30, 2013. Over the past co
Read more →HRTXA.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress
A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress REDWOOD CITY, Calif. May 10, 2013 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for first quarter ended March 31, 2013
Read more →HRTXA.P. Pharma Receives FDA Complete Response Letter for APF530 - Company Revises Projected Launch Timing from 2H 2013 to 1H 2014 - - Conference Call to Be Held at 8:30 a.m. Eastern Time
A.P. Pharma Receives FDA Complete Response Letter for APF530 Projected Launch Timing from 2H 2013 to 1H 2014 - - Conference Call to Be Held at 8:30 a.m. Eastern Time - REDWOOD CITY, Calif. March 28, 2013 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, t
Read more →HRTXA.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales
A.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales REDWOOD CITY, Calif. February 28, 2013 A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Jesse Hollingsworth as vice Jesse brings over a decade of highly relevant oncology sales experience, in
Read more →HRTXA.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530 Joel Schaedler named as Vice President of Market Access Daniel Martin named Vice Preside
A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530 Joel Schaedler named as Vice President of Market Access Daniel Martin named Vice President of Marketing REDWOOD CITY, Calif. December 17, 2012 A.P. Pharma, Inc. (OTCBB
Read more →HRTXA.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer REDWOOD CITY, Calif. December 13, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Mark S. Gelder, M.D. as senior vice presid
Read more →HRTXA.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate Progress
A.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate Progress REDWOOD CITY, Calif. November 5, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended September 30,
Read more →HRTXA.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer CITY, Calif. October 18, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen as senior vice president and chief commer
Read more →HRTXA.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission
A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application REDWOOD CITY, Calif. October 16, 2012 A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company s resubm
Read more →HRTXA.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting
A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting REDWOOD CITY, Calif. September 28, 2012 A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, today announced that it has resu
Read more →HRTXA.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development
A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development CITY, Calif. September 10, 2012 A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Thomas Pitler, Ph.D. as vice president of business development. Tom has extensive business deve
Read more →HRTXA.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress
A.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress REDWOOD CITY, Calif. August 2, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended June 30, 2012 a
Read more →HRTXA.P. Pharma Appoints Robert Rosen to Its Board of Directors
A.P. Pharma Appoints Robert Rosen to Its Board of Directors REDWOOD CITY, Calif. July 31, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen to its board of directors. We are delighted that Robert has ch
Read more →HRTXA.P. Pharma to Raise $53.6 Million in Common Stock Offering
A.P. Pharma to Raise $53.6 Million in Common Stock Offering REDWOOD CITY, Calif. July 25, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing institutional inve
Read more →HRTXA.P. Pharma Announces the Allowance of Three Patents Covering APF530 APF530 patent protection extended through 2024
A.P. Pharma Announces the Allowance of Three Patents Covering APF530 APF530 patent protection extended through 2024 REDWOOD CITY, Calif. July 10, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, announced today that the United States Patent and Trad
Read more →HRTXA.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting Poster at the Multinational Association of Supportive Car
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology International Symposi
Read more →HRTXA.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology Interna
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology International Symposium REDWOOD CITY, Calif. June 20, 2012 A.P. Pharma, Inc. (OTCBB: A
Read more →HRTXA.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control Phase 3 Data Abstract Accepted by American Society of Clinical Oncology for
A.P. Pharma Announces Study Finding Continuous Exposure to a Antagonist Using APF530 Provides Better Emetic Control Phase 3 Data Abstract Accepted by American Society of Clinical Oncology for Publication at Annual Meeting REDWOOD CITY, Calif. May 31, 2012 A.P. Pharma, Inc. (
Read more →HRTXA.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate Progress
A.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate Progress REDWOOD CITY, Calif. May 10, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2012 and hig
Read more →HRTXA.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530
A.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530 REDWOOD CITY, Calif. March 26, 2012 A.P. Pharma, Inc. (OTCBB: APPA) today reported fourth quarter and full year 2011 financial results and provided an update on its lead produ
Read more →HRTXLegal Disclaimer March 2012 2012. A.P. Pharma, Inc. All rights reserved. 2 This presentation contains forward looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward looking s
Actual results may differ materially from the results expected in our forward looking statements. We caution investors that forward looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. Company: A.P. Pharma,
Read more →HRTXA.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate Progress
A.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate Progress CITY, Calif. November 7, 2011 A.P. Pharma, Inc. (OTCQB: APPA.PK), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2011 and high
Read more →HRTXLegal Disclaimer September 2011 2011. A.P. Pharma, Inc. All rights reserved. 2 This presentation contains forward looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward looki
CINV Market Dynamics Injectable Drugs for the Number of Package Units Sold by Quarter Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 ALOXI ANZEMET KYTRIL KYTRIL Generic (GRANISETRON) ZOFRAN ZOFRAN
Read more →HRTXA.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate Progress
A.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate Progress REDWOOD CITY, Calif. - August 8, 2011 - A.P. Pharma, Inc. (OTCQB: APPA.PK), a specialty pharmaceutical company, today reported financial results for its second quarter ended June
Read more →HRTXA.P. Pharma to Raise $24 Million in Private Placement of Common Stock and Warrants Proceeds to Fund Resubmission Activities Relating to APF530
A.P. Pharma to Raise $24 Million in Private Placement of Common Stock and Warrants Proceeds to Fund Resubmission Activities Relating to APF530 NDA REDWOOD CITY, Calif. June 29, 2011 A.P. Pharma, Inc. (OTCQB: APPA.PK), a specialty pharmaceutical company, today announced that it
Read more →HRTXA.P. Pharma Announces First Quarter 2011 Financial Results and Recent Corporate Progress
A.P. Pharma Announces First Quarter 2011 Financial Results and Recent Corporate Progress REDWOOD CITY, Calif. - May 16, 2011 - A.P. Pharma, Inc. (OTCQB: APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2011 and hig
Read more →HRTXA.P. Pharma Announces Financing of Up to $4.5 Million and Names CEO and
A.P. Pharma Announces Financing of Up to $4.5 Million and Names CEO and COO REDWOOD CITY, Calif. April 25, 2011 A.P. Pharma, Inc. (OTCQB: APPA), a specialty pharmaceutical company, today announced that it has entered into definitive agreements with investors, including Tang Cap
Read more →HRTXA.P. Pharma Announces Fourth Quarter and Full Year 2010 Financial Results and Provides Corporate Update
A.P. Pharma Announces Fourth Quarter and Full Year 2010 Financial Results and Provides Corporate Update REDWOOD CITY, Calif. - March 28, 2011 - A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full
Read more →Competitive Position
How HRTX ranks across every disease it competes inCompetitive Position is a premium feature
See how HRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial